+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Viibryd (vilazodone; Allergan) Drug Overview 2019

  • PDF Icon


  • 17 Pages
  • March 2019
  • Region: Global
  • Citeline
  • ID: 4846112
Drug Overview
Viibryd (vilazodone; Allergan) belongs to a new class of antidepressants, combining selective serotonin reuptake inhibitor activity with partial 5-HT1A receptor agonism, in order to produce its therapeutic effect. This differentiates Viibryd from a variety of older antidepressants that act purely through reuptake inhibition, although the exact contribution of Viibryd’s dual mechanism to its overall profile is not known.

Clinical Data, the company that progressed Viibryd through its clinical development, announced the drug’s US Food and Drug Administration approval in January 2011. Just three weeks later, Clinical Data reached an agreement with Forest Laboratories to enter into a definitive merger agreement worth approximately $1.2bn, depending upon contingent value rights. Viibryd was then launched by Forest in August 2011, although Forest itself was acquired by Allergan in 2014 for $25bn.

Table of Contents

  • Drug Overview
  • Product Profiles

Figure 1: The author's drug assessment summary of Viibryd for depression
Figure 2: The author's drug assessment summary of Viibryd for depression
Figure 3: Viibryd sales for depression in the US, 2017–26
Table 1: Viibryd drug profile
Table 2: Approval history of Viibryd for depression in the US
Table 3: Late-phase trials of Viibryd for depression
Table 4: Viibryd ongoing Phase III trials in depression
Table 5: Viibryd for depression – SWOT analysis